Dose Fractionation in Neutron Capture Therapy for Malignant Melanoma

  • B. J. Allen
  • J. K. Brown
Part of the Basic Life Sciences book series (BLSC, volume 50)


Australia is entering a joint clinical trial with Japan for thermal Neutron Capture Therapy of selected patients with superficial local recurrent, local advanced and isolated metastatic malignant melanoma. The para-boronophenylalanine (BPA) compound will be used with a neutron fluence of about 1013 neutrons per cm2, to be delivered in a single dose. While in the initial trials of NCT, the single dose is a practical procedure, there may be advantages in dose fractionation, and these are considered in this paper.


Boron Atom Hypoxic Cell Boron Neutron Capture Therapy Dose Fraction Neutron Radiography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Proceedings of the Second Japan-Australia Workshop on Neutron Capture Therapy for Malignant Melanoma, to be published in Pigment Cell Research, 1988.Google Scholar
  2. 2.
    D. Barkla, B. J. Allen, J. K. Brown, and M. M. Mountford, Ref. 1.Google Scholar
  3. 3.
    Z. A. Abdel Malek, K. L. Kreutzfeld, M. M. Marwan, M. E. Hadley, V. J. Hruby, and B. C. Wilkes, Prolonged stimulation of 591 melanoma tyrosinase by [Nle4,D-Phi7] - substituted a - melanotropins. Cancer Res. 45: 4735 (1985).Google Scholar
  4. 4.
    M. L. Steinberg, and J. R. Whittaker, Stimulation of mela- notic expression in a melanoma cell line by theophylline. J. Cell. Physiol . 87: 265 (1976).Google Scholar
  5. 5.
    T. H. Lee, M. S. Lee, and M. Lee, Effects of a-MSH on melanogenesis and tyrosinase of B-16 melanoma. Endocrinology, 91: 1180 (1972).PubMedCrossRefGoogle Scholar
  6. 6.
    D. Gabel, S. Foster, R. G. Fairchild, Monte Carlo simulation of the biological effect of the -OB(n,a)7Li reaction in cells and tissue and its implication for boron neutron capture therapy, Radiation Res. 111 (1): 14 (1987).PubMedCrossRefGoogle Scholar
  7. 7.
    S. Wang, A. L. Lumanglas, J. Silva, V. Ruszala-Mallon, F. E. Durr, Internalisation and re-expression of antigens of human melanoma cells following exposure to monoclonal antibody. Cell Immunology, 106: 12 (1987).CrossRefGoogle Scholar
  8. 8.
    P. Hersey, Preclinical and phase I studies of monoclonal antibodies in melanoma - application to boron neutron capture therapy of melanoma, Ref. 1.Google Scholar
  9. H. R. Withers, H. D. Thames, Jr., L. J. Peters, Biological bases for high RBE values for late effects of neutron irradiation, Int. J. Radiat. Onc. Biol. Phys 8:2071 (1982).CrossRefGoogle Scholar
  10. 10.
    E. J. Hall, “Chemical and Pharmacological Modifiers, Radiobiology for the Radiologist,” Harper & Row Publishers, Inc., N.Y. (1978).Google Scholar
  11. 11.
    Y. Mishima, M. Ichihashi, M. Tsuji, M. Ueda, S. Hatta, T. Nakagawa, C. Tanaka, K. Taniyama, T. Suzuki, Prerequisites of first clinical trial for melanoma selective thermal neutron capture therapy, Neutron Capture Therapy Proc. Second Int. Sym., Tokyo, October, 1985, ed., H. Hatanaka, Nishimura, 230 (1986).Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • B. J. Allen
    • 1
  • J. K. Brown
    • 1
  1. 1.Australian Nuclear Science & Technology OrganisationLucas Heights Research LaboratoriesMenaiAustralia

Personalised recommendations